Abstract | BACKGROUND AND PURPOSE: EXPERIMENTAL APPROACH: Male CD-1 mice, which had the middle cerebral artery occluded, were treated (i.p.) with cinnamaldehyde. Neuroprotection by cinnamaldehyde was analysed by evaluating neurological deficit scores, brain oedema and infarct volume. Expressions of signal transduction molecules and inflammatory mediators were measured by Western blotting, qRT-PCR and immunohistochemical staining. Activation of NF-κB was assessed by Western blotting, immunohistochemistry and immunofluorescence. KEY RESULTS: CONCLUSIONS AND IMPLICATIONS:
|
Authors | Jingru Zhao, Xiangjian Zhang, Lipeng Dong, Ya Wen, Xiufen Zheng, Cong Zhang, Rong Chen, Ye Zhang, Yaoru Li, Tingting He, Xingyuan Zhu, Litao Li |
Journal | British journal of pharmacology
(Br J Pharmacol)
Vol. 172
Issue 20
Pg. 5009-23
(Oct 2015)
ISSN: 1476-5381 [Electronic] England |
PMID | 26234631
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 The British Pharmacological Society. |
Chemical References |
- Anti-Inflammatory Agents
- Ccl2 protein, mouse
- Chemokine CCL2
- E-Selectin
- Interleukin-1beta
- NF-kappa B
- Neuroprotective Agents
- RNA, Messenger
- TNF Receptor-Associated Factor 6
- Tlr4 protein, mouse
- Toll-Like Receptor 4
- Tumor Necrosis Factor-alpha
- Water
- Acrolein
- cinnamaldehyde
|
Topics |
- Acrolein
(analogs & derivatives, pharmacology, therapeutic use)
- Animals
- Anti-Inflammatory Agents
(pharmacology, therapeutic use)
- Brain
(drug effects, metabolism, pathology)
- Chemokine CCL2
(genetics)
- Disease Models, Animal
- E-Selectin
(genetics)
- Infarction, Middle Cerebral Artery
(drug therapy, metabolism, pathology)
- Interleukin-1beta
(genetics)
- Male
- Mice
- NF-kappa B
(metabolism)
- Neuroprotective Agents
(pharmacology, therapeutic use)
- RNA, Messenger
(metabolism)
- TNF Receptor-Associated Factor 6
(metabolism)
- Toll-Like Receptor 4
(metabolism)
- Tumor Necrosis Factor-alpha
(genetics)
- Water
(metabolism)
|